Amgen (AMGN) Stock Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
AMGN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Amgen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$381.50 |
| 52 Week High | US$377.05 |
| 52 Week Low | US$332.78 |
| Beta | 0.43 |
| 1 Month Change | -9.03% |
| 3 Month Change | 14.64% |
| 1 Year Change | 49.51% |
| 3 Year Change | 49.51% |
| 5 Year Change | 49.51% |
| Change since IPO | 149.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| AMGN | CL Biotechs | CL Market | |
|---|---|---|---|
| 7D | -2.6% | 0% | 0% |
| 1Y | 49.5% | 0% | 0% |
Return vs Industry: AMGN exceeded the CL Biotechs industry which returned 18.7% over the past year.
Return vs Market: AMGN exceeded the CL Market which returned 17.6% over the past year.
Price Volatility
| AMGN volatility | |
|---|---|
| AMGN Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in CL Market | 0% |
| 10% least volatile stocks in CL Market | 0% |
Stable Share Price: AMGN's share price has been volatile over the past 3 months compared to the CL market.
Volatility Over Time: AMGN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of CL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 31,500 | Bob Bradway | www.amgen.com |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI.
Amgen Inc. Fundamentals Summary
| AMGN fundamental statistics | |
|---|---|
| Market cap | US$208.49b |
| Earnings (TTM) | US$8.74b |
| Revenue (TTM) | US$38.10b |
Is AMGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMGN income statement (TTM) | |
|---|---|
| Revenue | US$38.10b |
| Cost of Revenue | US$10.71b |
| Gross Profit | US$27.39b |
| Other Expenses | US$18.64b |
| Earnings | US$8.74b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 16.17 |
| Gross Margin | 71.89% |
| Net Profit Margin | 22.95% |
| Debt/Equity Ratio | 490.3% |
How did AMGN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/20 00:59 |
| End of Day Share Price | 2026/09/17 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amgen Inc. is covered by 62 analysts. 31 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Emily Field | Barclays |